Project Grant R41HL147673

This three-year, $2.97 million Project Grant from the National Institutes of Health's Trans-NIH Research Support program will support the development of a novel lung research platform to probe pulmonary (patho)physiology in real-time at the cellular level. Trustees of Boston University will receive funding to create the LungEx platform, which includes long-term ex vivo maintenance of mouse and human lungs under near-physiological conditions. A key innovation is a "Crystal" ribcage that...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine to develop and test a novel lung precision drug delivery system (LPDDS) targeting lung myofibroblasts to treat lung fibrosis. The goal is to create "dual precision" bispecific therapeutics that can actively transport anti-fibrotic agents directly...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $306,748 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Mechanobiologix LLC. The award, with a performance period from September 2024 to September 2025, supports the development of a stiffness-based drug discovery platform to evaluate therapeutic and preventive capabilities of anti-fibrotic drugs for Idiopathic Pulmonary Fibrosis (IPF). The...

This three-year, $500,000 project grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) supports research at the University of Vermont to define environmental design criteria for directing differentiation of type 1 and type 2 lung alveolar epithelial cells. The University of Colorado-Denver and University of Iowa are sub-awardees on the project. Researchers will utilize novel tissue engineering approaches incorporating hydrogels derived from decellularized...

This R01 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop innovative approaches for therapeutic targeting of pulmonary endothelial cells to inhibit the progression of pulmonary fibrosis. The $695,403 award to the University of Arizona will fund research to determine whether restoring microvascular integrity through nanoparticle gene therapy or transplantation of FOXF1+cKIT+...

Trustees of Boston University received a $566,473 National Science Foundation Project Grant under the Engineering (47.041) federal grant program. The five-year award funds research utilizing a novel transparent ribcage platform termed LUNGEX to probe multiscale mechanobiology of pulmonary respiration-circulation coupling in real-time. The platform will allow unprecedented visualization of lung microphysiology dynamics at the cellular level across nearly the entire lung surface. Specific aims...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, Ohio. The 5-year award, beginning on Sep 1, 2024, will leverage advanced technologies and infrastructure to construct a multi-scale, AI-powered map of genetic and cellular mechanisms underlying normal and aberrant lung development in childhood interstitial lung disease (CHILD). The...

This $940,320 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project led by Vanderbilt University Medical Center (VUMC) to investigate the molecular mechanisms underlying chronic lung diseases such as pulmonary fibrosis and bronchopulmonary dysplasia. The key objectives are to: 1) develop a spatially-resolved molecular atlas of chronic parenchymal lung diseases, 2)...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $1,688,712 to Duke University to conduct research on the role of the protein tau in regulating alveolar epithelial cell structure and function during lung regeneration. The key objectives are to: 1) test the requirement of tau and the impact of a pathological tau variant in alveolar stem cell-mediated lung regeneration,...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $480,990 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Illinois to conduct research on the role of aerocytes, a recently identified lung cell population, in promoting alveolar epithelial regeneration following acute respiratory distress syndrome (ARDS). The project aims to establish the central role of aerocytes in regulating alveolar regeneration through signaling molecules like...